Dr. Hughes, Ph.D. is responsible for manufacturing process development and scale-up, and production of drug supplies for clinical trials according to cGMP requirements. Prior to joining Immuneering, Dr. Hughes held roles of increasing responsibility at Cidara Therapeutics, where he led the CMC development of REZZAYO™, a novel drug used for the treatment and prevention of systemic fungal infections, from Phase 1 through successful NDA and MAA approval and commercial launch. Prior to his work at Cidara, he held roles of increasing responsibility with Boehringer-Ingelheim’s Product and Process Development group for generic injectable drugs, culminating in its acquisition by Hikma Pharmaceuticals. Subsequent to the acquisition, he served as the Director of R&D for Hikma injectable products until December 2015. He also worked previously for PharmaForce, and Sonus Pharmaceuticals. Dr. Hughes received his Ph.D. in Organic Chemistry from the University of Notre Dame and completed a postdoctoral fellowship in Clinical Chemistry at the University of Washington School of Medicine. He received his B.S. in Chemistry from Eastern Washington University.